ClinicalTrials.gg
RecruitingNCT07929779GRANULOMICUpdated Nov 10, 2026

Differential Granulosa Cell Transcriptome Profiling as a Predictive Tool of Ongoing Pregnancy

An observational study in Infertility (IVF Patients), Oocyte Donation and PGT-A, sponsored by Vida Recoletas Sevilla. Recruiting at 1 site in Spain. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Vida Recoletas Sevilla · Observational

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 10, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Fertility problems are increasingly common in industrialized countries. It is estimated that 15-20% of couples of reproductive age have problems conceiving children naturally and the use of assisted reproductive treatment accounts for 1-3% of annual births. Among the causes of infertility, the female factor is responsible for approximately 40% of cases. The growing problem of infertility and the decline in the birth rate in Spain make absolutely necessary the improvement of assisted reproductive technology (ART). Actually, one of the main problems of ART is the election of the oocyte, as there is no method to select the best embryos for subsequent transfer. The average number of oocytes obtained from one woman in each cycle is 10-11, so the finding of a (some) biomarker(s) would have a great impact at a social and economic level and would commensurately reduce the economic cost of each cycle. Novel embryo assessment strategies are currently being developed and can be used alone or in combination with morphologic criteria. These include non-invasive methodologies as artificial intelligence using morphokinetic databases and the OMICS, like transcriptomic, proteomic and metabolomic. Among others, the transcriptome of the cumulus cells is a potentially valuable non-invasive biomarker. Indeed, it is already known that granulosa cells play a crucial role in the regulation of female fertility. The bi-directional communication between the oocyte and the surrounding cumulus cells is essential for the maturation of a developmentally competent oocyte, ovulation and fertilization, processes which are necessary for initiating and sustaining embryo development. Our work hypothesis is that the cumulus cell transcriptome would be directly related and give an essential information about oocyte maturation and fertilization ability.

Unfortunately, even though several studies on granulosa cell transcriptome analysis have been performed, the obtained data are still inconclusive. The main reason for this should be found in the study design which, in most cases, are performed in a small number of patients and presented a heterogeneous population.

Among others, there are great variations in the patients' age and physical characteristics, type of treatment, diagnosis, hormonal levels and endometrial receptivity. The main objective of this project is to find new unknown biomarker(s) of ongoing pregnancy by analyzing the whole transcriptome of the two granulosa cell layers surrounding the oocytes (cumulus cells and corona radiata). Specifically, the study aims to find a biomarker of oocyte maturity, of fertilization, of embryo quality, of euploid embryos, of pregnancy, early miscarriage or ongoing pregnancy, and finally, to find a correlation between these biomarkers and the morphokinetic of the embryos. An additional advantage of our project is the use of material that is obtained at the time of transvaginal ultrasound-guided oocyte retrieval but that is considered a waste and is usually discarded in Assisted Reproduction Centers. Therefore, the analysis of these cells does not suppose any change or bother for the women, in relation to the treatments of assisted reproduction.

02

Conditions studied

  • Infertility (IVF Patients)
  • Oocyte Donation
  • PGT-A

Browse trials for

Keywords

  • Granulosa
  • Transcriptomics
03

In context

Infertility

2,085 studies on the registry are indexed under Infertility; 357 are open to participants now.

This study's planned enrollment of 100 is below the median of 200 across 592 observational studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Vida Recoletas Sevilla is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women from 18 to 50 years of age attending VIDA Sevilla clinic for oocyte donation or reproductive treatment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced maternal age patients:

    • Between 40 and 45 years old, both inclusive
    • Patient at VIDA Sevilla
    • IVF cycle with own oocytes (fresh)
    • PGT-A cycle
    • Consent to perform embryo culture in Embryoscope
  • Oocyte donors:

    • Between 18 and 35 years old
    • Being an oocyte donor accepted by VIDA Sevilla according to standard donor selection criteria at this clinic
  • Oocyte recipients:

    • Patient at VIDA Sevilla
    • Younger than 51 years old
    • IVF cycle with fresh donor oocytes
    • Consent to perform embryo culture in Embryoscope
    • Matched donor already included in the study

Exclusion criteria

EXCLUSION CRITERIA:

  • Abnormal karyotype
  • Reproductive tract anomalies
  • Radio and chemotherapy treatments
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • AMA

    Female IVF patients aged 40 or older, undergoing ICSI + PGT-A treatment with own oocytes

  • FOD

    Fresh oocyte donation cycle patients (donor and recipient)

06

What researchers measure

Primary outcomes

  1. Identify predicitve biomarkers for ongoing pregnancy

    Ongoing pregnancy is defined by the detection of a fetal heartbeat in a pregnancy.

    Time frame: From enrollment to the end of follow-up at 8 weeks of gestational age.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Feb 2028, 26 months after the start.

Of 209 non-industry observational studies under Infertility, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 100. This study's planned 26 months is below that.

Counting every sponsor, half of 242 studies reached it within 39 months; a quarter within 16 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 10, 2026
StartActual
Dec 10, 2025
Primary completionEst.
Feb 2028
CompletionEst.
Jul 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07929779
Lead sponsor
Vida Recoletas Sevilla
Responsible party
Sponsor
First posted
Nov 10, 2026
Start date
Dec 10, 2025
Primary completion
Feb 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion